Quinazoline derivatives as inhibitors of P-38 .alpha.
US6184226A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 28, 1998 |
| Grant date | Feb 6, 2001 |
| Priority date | — |
| Expiry date | Aug 28, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention describes compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof and the pharmaceutically acceptable salts thereof PA1 wherein each R.sup.2 is independently a noninterfering substituent; PA1 m is an integer of 0-4; PA1 Z is CH or N; PA1 R.sup.1 is H, alkyl (1-6C) or arylalkyl optionally substituted on the aryl group with 1-3 substituents independently selected from alkyl (1-6C), halo, OR, NR.sub.2, SR, --OOCR, --NROCR, RCO, --COOR, --CONR.sub.2, --SO.sub.2 NR.sub.2, CN, CF.sub.3, and NO.sub.2, wherein each R is independently H or lower alkyl (1-4C); PA1 n is 0, 1 or 2; PA1 Ar is phenyl, pyridyl, indolyl, or pyrimidyl, each optionally substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR.sub.2, SR, --OOCR, --NROCR, RCO, --COOR, --CONR.sub.2, SO.sub.2 NR.sub.2, CN, CF.sub.3, and NO.sub.2, wherein each R is independently H or lower alkyl (1-4C); and PA1 R.sup.3 is a branched or cyclic alkyl group (5-7C) or is phenyl optionally substituted with 1-2 substituents which substituents are selected from the group consisting of alkyl (1-6C), halo, OR, NR.sub.2, SR, --OOCR, --NROCR, RCO, --COO…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.